PCO-371

DB14946InvestigationalSmall molecule

PCO-371 is under investigation in clinical trial NCT02475616 (A Single Ascending Dose Study of PCO371 in Healthy Volunteers).

Chemical structure of PCO-371
Formula / weight
C29H32F3N5O6S · 635.66 g/mol (avg)
Also known as
2,4-IMIDAZOLIDINEDIONE, 1-(3,5-DIMETHYL-4-(2-((4-OXO-2-(4-(TRIFLUOROMETHOXY)PHENYL)-1,3,8-TRIAZASPIRO(4.5)DEC-1-EN-8-YL)SULFONYL)ETHYL)PHENYL)-5,5-DIMETHYL- · non-peptide small molecule orally available agonist of the parathyroid hormone receptor type I
Code names
PC-0371 · PCO-371

Resolves to

Compound
UNIITE53TU0WSQCAS1613373-33-3ChEMBLCHEMBL3976807
Structure
InChIKeyLDZJFVOUPUFOHX-UHFFFAOYSA-NSMILESCC1=CC(=CC(C)=C1CCS(=O)(=O)N1CCC2(CC1)N=C(NC2=O)C1=CC=C(OC(F)(F)F)C=C1)N1C(=O)NC(=O)C1(C)C
Targets
Q03431PTH1R

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with PCO-371, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In